Thursday, July 3, 2025 7/3/2025

Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease

Award Number: R01AR081887
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 12/31/2027

Group Awards By:

View Award Description

Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease - PROJECT SUMMARY Disease modifying anti-rheumatic drugs (DMARDs) have greatly improved the treatment of inflammatory joint disease but cause generalized immunosuppression and increase the risk of serious infections and cancer. The pathogenic inflammation, a hallmark of autoimmune arthritis, can largely be ascribed to a deficiency in regulatory immune function. There is a critical need for anti-arthritic agents that can operate without impairing the immune system, which could also be combined with current DMARDs in patients who struggle to achieve durable remission. Towards this goal, the objective of the grant application is to validate a new strategy of intra-articularly (IA) drug delivery of an immunomodulatory agent that could promote durable disease remission in autoimmune arthritis without causing generalized suppression of immunity. Our agent leverages pre-existing regulatory T cells (Treg), widely recognized as the primary suppressors of autoreactive T cells, to promote a disease modifying anti-inflammatory effect. Recognizing that Treg are often insufficiently recruited to the inflamed joints, display abnormal levels of inflammation-induced instability and loss of function, our approach achieves localized expansion and stabilization of joint Treg and results in reduced inflammation and systemic disease modification in affected joints of arthritic mice without causing generalized immunosuppression. Here, we will validate our approach as a therapeutic option for inflammatory arthritis. In Aim 1 we will optimize our approach such that it durably enhances the magnitude and function of Treg for modulating inflammation. In Aim 2, we will systematically validate the mechanism of action of our agent and demonstrate the enhancement of disease-relevant Treg without suppressing non-specific T cell responses. In Aim 3, we will assess the adjunctive potential of our approach with a widely used first-line DMARD to reduce disease severity in mice that show partial DMARD responsiveness and assess whether the agent is effective in the ex-vivo enhancement of Treg isolated from DMARD-treated arthritis patients. Overall, these studies will advance our long-term goal of developing our approach to correct pathogenic immune dysregulation in autoimmune disorders affecting the joint and other tissues, arising from insufficient Treg function.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $436,969 )
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	1/8/2025	NON-COMPETING CONTINUATION	$405,436
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	3	6/5/2025	NON-COMPETING CONTINUATION	$31,533
														Subtotal = $436,969

Issue Date FY: 2024 ( Subtotal = $667,339 )
2024	2024	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	5/30/2024	NON-COMPETING CONTINUATION	$48,159
2024	2024	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	1/9/2024	NON-COMPETING CONTINUATION	$619,180
														Subtotal = $667,339

Issue Date FY: 2023 ( Subtotal = $678,420 )
2023	2023	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	1/30/2023	NEW	$449,661
2023	2023	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DRIVE	LA JOLLA	CA	92093	SAN DIEGO	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	1	9/14/2023	SUPPLEMENT FOR EXPANSION	$228,759
														Subtotal = $678,420

Grand Total All Awards = $1,782,728

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease

Award Number: R01AR081887

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 12/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer